AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder

HEIDELBERG, Germany, Nov 11 (Bernama) -- In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease.

With few RNA-based programs in development for rare diseases, Child’s Cure Genetic Research and AGC Biologics will collaborate to identify a viable path for a new mRNA therapeutic that mimics the protein made by the CDKL5 gene. The intent of the protein-sustaining treatment is to reduce seizures, improve neurological development, and help patients—many of whom are babies and young children—gain control from debilitating symptoms that impede their health and potential.

For full news, click here